Burning Rock Biotech vs Veracyte
BNR and VCYT side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BNR and VCYT compare
Veracyte grew revenue faster over the last twelve months (17.3% versus 4.6% for Burning Rock Biotech).
Veracyte keeps more of each dollar of sales as profit, with a net margin of 20.4% compared with −10.3% at Burning Rock Biotech.
Veracyte scores higher on the StockData Score (16 against 4 for Burning Rock Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BNR | VCYT |
|---|---|---|
| Size and price | ||
| Market cap | – | $1.9B |
| Share price | $12.50 | $24.23 |
| Change, 1 year | 6.5% | −38.4% |
| Change, 5 years | −90.9% | −41.7% |
| Beta (5Y) | 2.52 | 1.92 |
| Employees | 667 | 755 |
| StockData Score | ||
| Total score | 4 | 16 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 1 | 3 (better) |
| Performance score | 1 | 3 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 17.3× |
| P/S | – | 3.5× |
| P/B | – | 1.4× |
| EV/EBITDA | – | 13.0× |
| P/FCF | – | 11.7× |
| FCF yield | – | 8.5% |
| Fair value | – | $36.51 |
| Margin of safety | – | 33.6% |
| Growth | ||
| Revenue growth (TTM) | 4.6% | 17.3% (better) |
| Revenue growth, 5Y average | 4.6% | 34.5% (better) |
| Net income growth (TTM) | – | 335% |
| EPS growth (TTM) | – | 324% |
| Profitability | ||
| Gross margin | 74.7% (better) | 71.7% |
| Operating margin | −10.2% | 18.8% (better) |
| Net margin | −10.3% | 20.4% (better) |
| FCF margin | −6.2% | 29.5% (better) |
| Return on equity | −9.9% | 8.8% (better) |
| Return on invested capital | −72.5% | 10.0% (better) |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.00 |
| Current ratio | 2.99 | 9.16 (better) |
| Altman Z-score | – | 12.65 |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 1.8% | 111% |
| Held by insiders | 19.0% | 1.7% |
| Insider net buying, 12 months | $11.6M (better) | −$18.6M |
| Short interest, % of float | – | 12.1% |
Go deeper
- BNR stock overview
- BNR income statement
- BNR valuation and score
- VCYT stock overview
- VCYT income statement
- VCYT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.